Results 41 to 50 of about 1,414 (186)

Efficacy of Conbercept in the Treatment of Choroidal Neovascularization Secondary to Pathologic Myopia [PDF]

Frontiers in Medicine, 2021
Purpose: To observe the clinical efficacy of conbercept in the treatment of choroidal neovascularization (CNV) secondary to pathologic myopia.Methods: We used retrospective analysis of the clinical data of 20 patients (24 eyes) with pathologic myopia choroidal neovascularization (PM-CNV).
Hui Lu, Tao Yue, Na Liu, Zuo-Fen Wang, Gai-Xia Zhai, Dong-Ming Mi, Jing Zhang, Shao-Peng Wang   +7 more
openaire   +3 more sources

Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model

Frontiers in Medicine, 2021
Background: With the advent of aging society of China, fundus diseases related to pathological neovascularization, including age-related macular degeneration (AMD), diabetic macular edema (DME), and pathological myopia (PM), have become an increasingly ...
Zhuang Cui, Wei Zhou, Qinxue Chang, Tiantian Zhang, Hui Wang, Xiangda Meng, Yuanyuan Liu, Hua Yan   +7 more
doaj   +1 more source

Structural characterization of a recombinant fusion protein by instrumental analysis and molecular modeling. [PDF]

PLoS ONE, 2013
Conbercept is a genetically engineered homodimeric protein for the treatment of wet age-related macular degeneration (wet AMD) that functions by blocking VEGF-family proteins.
Zhigang Wu, Peng Zhou, Xiaoxin Li, Hui Wang, Delun Luo, Huaiyao Qiao, Xiao Ke, Jian Huang   +7 more
doaj   +1 more source

Efficacy of conbercept after switching from bevacizumab/ranibizumab in eyes of macular edema secondary to central retinal vein occlusion [PDF]

International Journal of Ophthalmology, 2022
AIM: To explore the efficacy of conbercept after switching from bevacizumab/ranibizumab in eyes of central retinal vein occlusion (CRVO) through optical coherence tomography angiography (OCTA). METHODS: Patients with prior treatment of a minimum of three
Tong Zhao, You Chen, Hong-Song Zhang, Yi Chen, Zhi-Jun Wang   +4 more
doaj   +1 more source

Intravitreal Double-Dose Conbercept Injection for the Treatment of Neovascular Age-Related Macular Degeneration: A Pilot Real-Life Clinical Practice Study. [PDF]

Clin Ophthalmol
Tianwei Qian,1,* Yanping Zhou,2,* Hao Zhou,1 Wenshu Wu,1 Yuanzhi Yuan,2 Suqin Yu,1 Xun Xu1 1Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, People’s Republic of China; 2Department of ...
Qian T, Zhou Y, Zhou H, Wu W, Yuan Y, Yu S, Xu X.   +6 more
europepmc   +2 more sources

Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study

, 2021
BACKGROUND: To demonstrate the efficacy and safety of intravitreal injections of conbercept versus laser photocoagulation in the treatment of diabetic macular oedema (DME). METHODS: A 12-month multicentre, randomised, double-masked, double-sham, parallel
Liu, Xiaoling, Li, Xiaoxin, Wang, Xinguo, Rosenfeld, Philip, Heier, Jeffrey S, Xu, Xun, Kaiser, Peter, Ye, Junjie, Chen, Shaojun, Liu, Kun, Liu, Yuling, Wang, Hanying, He, Wei, Wu, Quan, Zhang, Feng, Song, Yanping, Zhang, Junjun, Ke, Xiao, Tao, Shanshan, Li, Zhiqing, Zhang, Xuedong, Liu, Lin, Wang, Yusheng, Wu, Zhifeng, Ye, Jian, Liang, Xiaoling, Li, Jie, Fan, Ke   +27 more
core   +1 more source

Presentation_1_Microvascular Changes After Conbercept Intravitreal Injection of PDR With or Without Center-Involved Diabetic Macular Edema Analyzed by OCTA.pdf

, 2022
PurposeTo investigate the intravitreal injection of conbercept as a treatment strategy for proliferative diabetic retinopathy (PDR) with or without center-involved diabetic macular edema (CI-DME) and evaluate its effect on the microvascular changes in ...
Tingting Liu (267387), Meng Feng (2178230), Wenhao Li (1424413), Wei Lin (6475), Qingxu Wang (12275354), Qingjun Zhou (178655), Tong Liu (107783), Wenqi Wang (610469), Jitian Guan (8145513), Zhongyu Ma (12275357), Xiao Xie (133080)   +10 more
core   +1 more source

Recent Investigations on Pathogenesis, Biomarkers, Epigenetics, and Emerging Therapeutic Strategies to Modulate Multiple Signaling Pathways in Diabetic Retinopathy. [PDF]

J Ophthalmol
Background Diabetic retinopathy (DR) is a progressive microvascular complication related to diabetes mellitus and remains a profound cause of vision impairment and blindness globally. In addition to its ocular manifestations, DR is increasingly recognized as a main risk factor for systemic diseases, including cardiovascular and neurodegenerative ...
Huang Z, Wei J, Yang D.
europepmc   +2 more sources

One-year outcomes of intravitreal conbercept combined rescue therapy for polypoidal choroidal vasculopathy in a Chinese population: a real-life clinical data [PDF]

International Journal of Ophthalmology, 2019
AIM: To evaluate the real-life clinical outcomes of intravitreal injection of conbercept combined rescue therapy for polypoidal choroidal vasculopathy (PCV). METHODS: This was an open label, single center, and interventional study. All enrolled patients
Hui-Jun Qi, En-Zhong Jin, Ming-Wei Zhao
doaj   +1 more source

Serum levels of cytokines in infants treated with conbercept for retinopathy of prematurity [PDF]

Scientific Reports, 2020
Abstract Intravitreal anti-vascular endothelial growth factor (VEGF) agents have revolutionized the treatment of retinopathy of prematurity (ROP); however, there are concerns regarding the potential systemic complications caused by those treatments.
Yong Cheng, Xiaolei Zhu, Dandan Linghu, Yongsheng Xu, Jianhong Liang   +4 more
openaire   +2 more sources